Company
Basilea Pharmaceutica Ltd. is a biopharmaceutical company headquartered in Basel,
Switzerland, listed on the SWX Swiss Exchange (SWX:BSLN). Our focus is on the discovery,
development and commercialization of innovative medicines to satisfy high medical and
patient needs in the hospital and specialty pharmaceutical setting. The Company has a fully integrated R&D organization and is currently building its sales and marketing organization in the U.S., Canada and major European markets. Basilea employs more than 250 people worldwide.
Portfolio
The broad and balanced late-stage product portfolio includes novel treatments for resistant bacterial infections, systemic fungal infections, and severe skin diseases. The highly competitive product pipeline comprises two drug candidates in pre-registration, one in clinical phase III as well as substantial innovative early-stage programs.
Products
The three high-potential products in late-stage development are ceftobiprole, an anti-MRSA broad-spectrum cephalosporin antibiotic, which is developed in collaboration with Johnson & Johnson; isavuconazole, a novel broad-spectrum antifungal for the treatment of severe invasive fungal infections; and alitretinoin, an oral retinoid for the treatment of patients with chronic hand eczema who do not respond to topical steroids.
Vision
We strive to lead in integrated research, development and commercialization in the hospital and specialty care setting. We aspire to provide innovative medications to patients with high medical needs through a sustainable business while maximizing shareholder value.
